\
&
Contact us
\
&
Contact us
This was 4 years ago
Locationvirtual
ProgrammesThe Estonian Research Council (ETAg) organises a webinar on the open access publishing requirements in Horizon Europe. The webinar consists of two parts: the first hour will be held in English and the second part in Estonian. The speaker in the first hour is Ms. Victoria Tsoukala (Policy Officer on Open Access and European Open Science Cloud) from the European Commission. Topics that will be covered are the research publishing requirements in Horizon Europe as well as an introduction to the new open access publishing platform Open Research Europe (ORE). The seond half will provide an insight to the subject matter specifically in the Estonian context.
Researchers and research administrators whom inted to apply for Horizon Europe are welcome to take part in this free webinar. Please register beforehand via https://etag.clickmeeting.com/avatud-juurdepaas-euroopa-horisont-ja-eesti-kontekst-open-access-in-horizon-europe/register
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
